PARP1 and neoplasm: Other pre-clinical cancer studies also demonstrated that the inhibition of PARP-1/2 retained NK cell viability and primed tumor cells to NK-cell-mediated killing in various cancer models, such as breast, prostate, NSLC, and chronic myeloid leukemia [333,334].